DIAGEN UPDATES ON DIABETES - Mars 2025
- DiaGen
- 28 mar
- Tempo di lettura: 2 min
#newsletter 4: UPDATES ON DIABETES
Personalizing diabetes therapy to improve glucose control
A recent publication in the scientific journal The Lancet (March 1st, 2025) shows a new model to predict the best type II diabetes therapy for a patient. This model uses individual clinical features and laboratory parameters of patients to select the most effective drug therapy to control glycemia for each subject. This model performs the analysis considering 5 drug classes for the treatment of type II diabetes (DPP-4 inhibitors, GLP-1R agonists, sulfonylureas, SGLT2 inhibitors, thiazolidinediones).
The results indicate that this “five-drug class model” provides accurate information on the patient, optimizes glycemic control, reduces by almost 40% the risk of glycemia failure, lowers the chance of adverse cardiovascular events and renal complications in a 5-years period.
This is a low-cost and easy to be implemented analysis to identify the most effective therapy for a type II diabetic patient. This model can have a widespread use in different countries and improves the patient care of type II diabetic patients.
Diabetes Numbers
The incidence of type II diabetes is rapidly increasing worldwide; in 1990, the number of patients was 200 million and, in 2022, the estimated number was 828 million (The Lancet, November 2024). In the UK, since 2016, type II diabetes increased by 40% in kids and adults under 40 years old. Of note, obesity and abdominal fat are the main risk factors for type II diabetes and obesity has been also increasing all over the world at alarming rates. In 2022, 2 billion people 18 and older were adults overweight, and 890 million were considered obese. This disease represents a huge burden for the population and for the health system. This tendency needs to be reversed, and investment is required to safeguard an appropriate nutrition of the population, maintenance of a healthy lifestyle and scientific research on this topic (The Lancet Diabetes & Endocrinology, July 2024, World Health Organization).
DiaGen is a Geneva based non-profit association that supports high-quality research in the field of diabetes.
Contact us:
Thank you.
Commentaires